Top in ID: Paxlovid does not reduce long COVID risk; oral antibiotics safe in transplants

Paxlovid, an oral antiviral approved by the FDA in May 2023, did not reduce the risk for long COVID among vaccinated, nonhospitalized patients who received it within a month of their first SARS-CoV-2 infection, a study showed.
Researchers found that the risk for long COVID was similar between those who received Paxlovid and those who did not.
“We were surprised,” Matthew S. Durstenfeld, MD, MAS, a cardiologist and assistant professor of medicine at the University of California, San Francisco, told Healio. “We expected that Paxlovid would prevent long COVID and that those who

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart